MarginsXMarginsX
Home › Data Desk › Sonoma Pharmaceuticals Inc. files an S-3 shelf registration

MarginsX Data Desk · Offerings · Dilution · Warrants and inducements · Pet products · Aesthetics and dermatology

Sonoma Pharmaceuticals Inc. files an S-3 shelf registration

Sonoma Pharmaceuticals Inc. (SNOA) filed an S-3 on Nov 13, 2026, a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.

Line chart of Sonoma Pharmaceuticals Inc. (SNOA) daily closes from Jul 6, 2026 to Nov 13, 2026, with the offering filing on Nov 13, 2026 marked.

Cash and dilution

It reported cash of $4.6M as of Sep 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

At its recent quarterly burn rate that cash lasts about 20.7 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Its share count rose 197.6% over the past year. (Company health, computed by us from SEC filings and XBRL, Nov 10, 2026)

The stock

The Nasdaq screener puts its market value at $5.5M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/SNOA)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameSonoma Pharmaceuticals Inc.Source2026-11-13
FormS-3Source2026-11-13
WhoSonoma Pharmaceuticals Inc. (SNOA)Source2026-11-13
SymbolSNOASource2026-11-13
FiledNov 13, 2026Source2026-11-13
Cash4,609,000 USDSource2026-09-30
Cash dateSep 30, 2026Source2026-09-30
Runway20.7 monthsSource2026-09-30
Dilution 1y197.6 %Source2026-11-10
Cap5,517,137 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS